Study limitation
MYOCARDIAL INFARCTION, BLIND
Our study has some limitations. Firstly, this study is a single-blind, randomized, placebo-controlled clinical trial. The single-blind design may affect patients’ selection. And the randomization is not performed by an independent system; the block size is small. These factors may also cause bias. However, to minimize bias as much as possible, we have taken some measures like using objective primary outcome, and doctors are blind to the randomization scheme and personnel training. Secondly, based on our inclusion and exclusion criteria, this study recruited “low-risk” patients. However, the effect of colchicine on myocardial protection in “high-risk” patients was not examined yet. Thirdly, we utilized cTnT to evaluate the perioperative myocardial infarction. In other words, whether colchicine could improve clinical outcomes needs further confirmation. Even though cTnT has been proven to be a well-validated biomarker for postoperative outcome [